PANews 11月15日消息，据Spot On Chain监测，除了Wintermute之外，GSR Markets已成为TARS AI的市场做市商。昨日，GSR ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...

This Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) report was produced by Stock Traders Daily. Over the past 20 years our metholdology has been refined to help identify strategies for both individual ...

深潮 TechFlow 消息，11 月 15 日，据 Spot On Chain 监测，GSR Markets 或已成为 TARS AI（TAI）的市场做市商。昨日，GSR Markets 收到了 500 万枚 TAI（约合 78.9 ...

Tarsus Pharmaceuticals在财务业绩的上下线方面持续表现出色，促使该公司修正其估计和目标价。公司的XDEMVY自推出以来仅一年多就实现了约2.5亿美元的年化销售额。这一成功导致该公司决定将产品的销售预测上调两位数百分比，超过了此前对2024年第一季度的估计。

Shares of Tarsus Pharmaceuticals, Inc. (TARS) have gained 22.4% over the past four weeks to close the last trading session at $44.83, but there could still be a solid upside left in the stock if short ...

Tarsus Pharmaceuticals, Inc. (TARS) 宣布2024年第三季度业绩强劲，其眼科治疗产品XDEMVY（用于治疗蠕形螨睑缘炎（DB）和睑板腺功能障碍（MGD））的净产品销售额创下4800万美元的纪录。公司已扩大销售团队，并获得了广泛的商业和医疗保险覆盖。 Tarsus还计划在2024年底前获得两种额外治疗方法的FDA批准，并预计XDEMVY将在2027年下半年获得欧洲批 ...

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...